Comprehensive Stock Comparison
Compare XOMA Corporation (XOMAP) vs Royalty Pharma plc (RPRX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  XOMAP | 498.7% revenue growth vs RPRX's 5.1% |
| Value |  RPRX | Lower P/E (9.7x vs 39.1x) |
| Quality / Margins | XOMAP | 46.1% net margin vs RPRX's 32.6% |
| Stability / Safety | XOMAP | Beta 0.13 vs RPRX's 0.36 |
| Dividends | XOMAP | 1.8% yield, vs RPRX's 1.4% |
| Momentum (1Y) | RPRX | +44.5% vs XOMAP's +9.2% |
| Efficiency (ROA) | XOMAP | 8.3% ROA vs RPRX's 4.0%, ROIC -37.6% vs 6.7% |
Who Each Stock Is For
Income & stability
XOMAPDividend streak 0 yrs, beta 0.13, yield 1.8%
Growth exposure
XOMAPRev growth 498.7%, EPS growth 59.2%, 3Y rev CAGR -9.3%
Long-term compounding (10Y)
XOMAP51.6% 10Y total return vs RPRX's 16.3%
Sleep-well-at-night portfolio
XOMAPLower volatility, beta 0.13, current ratio 5.15x
Defensive / Recession hedge
XOMAPBeta 0.13, yield 1.8%, current ratio 5.15x
Business Model
What each company does and how it makes money
XOMA Corporation is a biotechnology royalty aggregator that acquires future economic rights to pre-commercial therapeutic candidates licensed to pharmaceutical partners. It generates revenue primarily through milestone payments and royalties from its portfolio of approximately 70 early to mid-stage clinical assets — with no single asset dominating its income stream. The company's moat lies in its specialized expertise in evaluating and structuring royalty agreements for complex biotech assets, creating a diversified portfolio of potential future revenue streams.
Royalty Pharma is a specialized investment firm that acquires royalty interests in approved and development-stage biopharmaceutical products. It generates revenue primarily from royalty payments on approximately 35 marketed therapies — with its largest assets including cystic fibrosis drug Trikafta and HIV treatment Biktarvy — which provide predictable cash flows. The company's competitive advantage lies in its deep expertise in valuing complex biopharmaceutical royalties and its extensive industry relationships that provide access to proprietary deal flow.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
RPRX 2XOMAP 0RPRX3/4 metricsRPRX4/6 metricsRPRX leads in 2 of 6 categories — strongest in Valuation Metrics and Total Returns. 4 categories are tied.
Financial Metrics (TTM)
RPRX is the larger business by revenue, generating $2.3B annually — 49.9x XOMAP's $47M. XOMAP is the more profitable business, keeping 46.1% of every revenue dollar as net income compared to RPRX's 32.6%. On growth, XOMAP holds the edge at +29.9% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | XOMAPXOMA Corporation | RPRXRoyalty Pharma plc |
|---|---|---|
| RevenueTrailing 12 months | $47M | $2.3B |
| EBITDAEarnings before interest/tax | $13M | $1.5B |
| Net IncomeAfter-tax profit | $22M | $765M |
| Free Cash FlowCash after capex | $5M | $2.4B |
| Gross MarginGross profit ÷ Revenue | +93.6% | +100.0% |
| Operating MarginEBIT ÷ Revenue | -15.0% | +65.2% |
| Net MarginNet income ÷ Revenue | +46.1% | +32.6% |
| FCF MarginFCF ÷ Revenue | +11.4% | +102.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +29.9% | +7.9% |
| EPS Growth (YoY)Latest quarter vs prior year | +144.0% | -44.8% |
Valuation Metrics
| Metric | XOMAPXOMA Corporation | RPRXRoyalty Pharma plc |
|---|---|---|
| Market CapShares × price | $321M | $7.1B |
| Enterprise ValueMkt cap + debt − cash | $338M | $15.4B |
| Trailing P/EPrice ÷ TTM EPS | -15.79x | 26.55x |
| Forward P/EPrice ÷ next-FY EPS est. | 39.12x | 9.72x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 9.89x |
| Price / SalesMarket cap ÷ Revenue | 11.26x | 2.98x |
| Price / BookPrice ÷ Book value/share | 3.72x | 2.73x |
| Price / FCFMarket cap ÷ FCF | — | 2.85x |
Profitability & Efficiency
XOMAP delivers a 20.1% return on equity — every $100 of shareholder capital generates $20 in annual profit, vs $8 for RPRX. RPRX carries lower financial leverage with a 0.91x debt-to-equity ratio, signaling a more conservative balance sheet compared to XOMAP's 1.46x.
| Metric | XOMAPXOMA Corporation | RPRXRoyalty Pharma plc |
|---|---|---|
| ROE (TTM)Return on equity | +20.1% | +8.0% |
| ROA (TTM)Return on assets | +8.3% | +4.0% |
| ROICReturn on invested capital | -37.6% | +6.7% |
| ROCEReturn on capital employed | -19.4% | +8.7% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 1.46x | 0.91x |
| Net DebtTotal debt minus cash | $18M | $8.3B |
| Cash & Equiv.Liquid assets | $102M | $619M |
| Total DebtShort + long-term debt | $119M | $9.0B |
| Interest CoverageEBIT ÷ Interest expense | 2.20x | 5.66x |
Total Returns (with DRIP)
A $10,000 investment in XOMAP five years ago would be worth $14,545 today (with dividends reinvested), compared to $12,113 for RPRX. Over the past 12 months, RPRX leads with a +44.5% total return vs XOMAP's +9.2%. The 3-year compound annual growth rate (CAGR) favors RPRX at 12.3% vs XOMAP's 9.2% — a key indicator of consistent wealth creation.
| Metric | XOMAPXOMA Corporation | RPRXRoyalty Pharma plc |
|---|---|---|
| YTD ReturnYear-to-date | -1.9% | +22.2% |
| 1-Year ReturnPast 12 months | +9.2% | +44.5% |
| 3-Year ReturnCumulative with dividends | +30.2% | +41.7% |
| 5-Year ReturnCumulative with dividends | +45.4% | +21.1% |
| 10-Year ReturnCumulative with dividends | +51.6% | +16.3% |
| CAGR (3Y)Annualised 3-year return | +9.2% | +12.3% |
Risk & Volatility
XOMAP is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than RPRX's 0.36 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RPRX currently trades 99.8% from its 52-week high vs XOMAP's 86.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | XOMAPXOMA Corporation | RPRXRoyalty Pharma plc |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.13x | 0.36x |
| 52-Week HighHighest price in past year | $30.00 | $47.34 |
| 52-Week LowLowest price in past year | $24.96 | $29.66 |
| % of 52W HighCurrent price vs 52-week peak | +86.9% | +99.8% |
| RSI (14)Momentum oscillator 0–100 | 42.2 | 75.1 |
| Avg Volume (50D)Average daily shares traded | 778 | 3.0M |
Analyst Outlook
Wall Street rates XOMAP as "Buy" and RPRX as "Buy". For income investors, XOMAP offers the higher dividend yield at 1.79% vs RPRX's 1.42%.
| Metric | XOMAPXOMA Corporation | RPRXRoyalty Pharma plc |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | — | $49.40 |
| # AnalystsCovering analysts | 9 | 11 |
| Dividend YieldAnnual dividend ÷ price | +1.8% | +1.4% |
| Dividend StreakConsecutive years of raises | 0 | 2 |
| Dividend / ShareAnnual DPS | $0.47 | $0.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Dec 20 | Mar 26 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | 100 | 106.74 | +6.7% |
| Royalty Pharma plc (RPRX) | 100 | 100.92 | +0.9% |
XOMA Corporation (XOMAP) returned +45% over 5 years vs Royalty Pharma plc (RPRX)'s +21%. A $10,000 investment in XOMAP 5 years ago would be worth $14,545 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | $6M | $28M | +412.0% |
| Royalty Pharma plc (RPRX) | $1.6B | $2.4B | +48.8% |
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -9.6% | -48.5% | -404.3% |
| Royalty Pharma plc (RPRX) | 75.7% | 32.4% | -57.2% |
Chart 4P/E Ratio History — 6 Years
| Stock | 2020 | 2025 | Change |
|---|---|---|---|
| Royalty Pharma plc (RPRX) | 19.3 | 21.7 | +12.4% |
Royalty Pharma plc has traded in a 11x–404x P/E range over 6 years; current trailing P/E is ~27x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| XOMA Corporation (XOMAP) | -4.72 | -1.65 | +65.0% |
| Royalty Pharma plc (RPRX) | 1.99 | 1.78 | -10.7% |
Chart 6Free Cash Flow — 5 Years
XOMA Corporation generated $-14M FCF in 2024 (-260% vs 2021). Royalty Pharma plc generated $2B FCF in 2025 (+23% vs 2021).
XOMAP vs RPRX: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is XOMAP or RPRX a better buy right now?
Royalty Pharma plc (RPRX) offers the better valuation at 26.6x trailing P/E (9.7x forward), making it the more compelling value choice. Analysts rate XOMA Corporation (XOMAP) a "Buy" — based on 9 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — XOMAP or RPRX?
On forward P/E, Royalty Pharma plc is actually cheaper at 9.7x.
03Which is the better long-term investment — XOMAP or RPRX?
Over the past 5 years, XOMA Corporation (XOMAP) delivered a total return of +45.4%, compared to +21.1% for Royalty Pharma plc (RPRX). A $10,000 investment in XOMAP five years ago would be worth approximately $15K today (assuming dividends reinvested). Over 10 years, the gap is even starker: XOMAP returned +51.6% versus RPRX's +16.3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — XOMAP or RPRX?
By beta (market sensitivity over 5 years), XOMA Corporation (XOMAP) is the lower-risk stock at 0.13β versus Royalty Pharma plc's 0.36β — meaning RPRX is approximately 170% more volatile than XOMAP relative to the S&P 500. On balance sheet safety, Royalty Pharma plc (RPRX) carries a lower debt/equity ratio of 91% versus 146% for XOMA Corporation — giving it more financial flexibility in a downturn.
05Which has better profit margins — XOMAP or RPRX?
Royalty Pharma plc (RPRX) is the more profitable company, earning 32.4% net margin versus -48.5% for XOMA Corporation — meaning it keeps 32.4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: RPRX leads at 65.6% versus -140.3% for XOMAP. At the gross margin level — before operating expenses — RPRX leads at 100.0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is XOMAP or RPRX more undervalued right now?
On forward earnings alone, Royalty Pharma plc (RPRX) trades at 9.7x forward P/E versus 39.1x for XOMA Corporation — 29.4x cheaper on a one-year earnings basis.
07Which pays a better dividend — XOMAP or RPRX?
All stocks in this comparison pay dividends. XOMA Corporation (XOMAP) offers the highest yield at 1.8%, versus 1.4% for Royalty Pharma plc (RPRX).
08Is XOMAP or RPRX better for a retirement portfolio?
For long-horizon retirement investors, XOMA Corporation (XOMAP) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.13), 1.8% yield). Both have compounded well over 10 years (XOMAP: +51.6%, RPRX: +16.3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between XOMAP and RPRX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.